BioSpace News Archive

Mustang Bio, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2019.

Results demonstrate in vivo use of a phage cocktail effectively eradicated a bacterial target hypothesized as a disease modifying target in Primary Sclerosing Cholangitis (PSC)

LHC Group, Inc. (NASDAQ: LHCG) announced today that the Company is presenting at the Stephens Nashville Investment Conference in Nashville, Tenn. on Friday, November 15, 2019 at 9:45 a.m. Central time and a live webcast will be available.

Celldex Therapeutics, Inc. reported business and financial highlights for the third quarter ended September 30, 2019.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2019 financial results and provided a business update.

Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax’’ or the ''Company’’), an outcome-driven connected healthcare company, today announced its wholly-owned subsidiary Parallax Behavioral Health, Inc. has entered into vertical market licenses and technology integration agreements within the financial technology, human resource, lifestyle and healthcare fields.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that the FDA has approved a request for Investigational New Drug (“IND”) status for its drug candidate WP1066 to be used in a Phase 1 clinical trial for the treatment of children with recurrent or refractory malignant brain tumors.

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for nanatinostat in combination with valganciclovir for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoid malignancies.

MilliporeSigma today announced that it has signed a license agreement providing Evotec SE access to MilliporeSigma’s foundational CRISPR intellectual property.

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development Officer